Cost-effectiveness of first-line pembrolizumab monotherapy in PD-L1-high metastatic non-small cell lung cancer in Australia: evidence from trials and real-world practice.
Journal: International journal of clinical pharmacy
•
Abstract
Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.
Subjects & Keywords
How to Cite this Article
Teppala S, Koo J, Tan ECK, et al. (2026). "Cost-effectiveness of first-line pembrolizumab monotherapy in PD-L1-high metastatic non-small cell lung cancer in Australia: evidence from trials and real-world practice.". International journal of clinical pharmacy. https://doi.org/10.1007/s11096-026-02202-3